PALO ALTO, Calif. - (BUSINESS WIRE) - Bayhill Therapeutics, Inc. (“Bayhill”) announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of shares of its common stock. Copies of the Bayhill registration statement on Form S-1 can be accessed over the internet through the SEC’s website at edgar.sec.gov. The number of shares to be offered and the price range for the offering have not yet been determined. All of the shares of common stock to be sold in this offering are proposed to be sold by Bayhill.

Pacific Growth Equities, LLC and Lazard Capital Markets LLC are acting as joint book-running managers for the offering. Merriman Curhan Ford & Co. and Punk, Ziegel & Company are co-managers. This offering will be made only by means of a prospectus. Copies of the preliminary prospectus for this offering may be obtained, when available, from Pacific Growth Equities, LLC, One Bush Street, Suite 1700, San Francisco, CA 94104, or from Lazard Capital Markets LLC, 30 Rockefeller Plaza, New York, NY 10020.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.


About Bayhill Therapeutics
Bayhill is a clinical-stage biopharmaceutical company using its proprietary therapeutic platform to develop a pipeline of novel products to treat autoimmune diseases in a fundamentally new manner. The company’s product candidates are designed to restore the immune system to its normal state, which is known as “tolerance.” Bayhill’s lead product candidate, BHT-3009, for the treatment of multiple sclerosis has completed a Phase II proof-of-concept clinical trial. Its second product candidate, BHT-3021, for the treatment of type 1 diabetes, is currently in a Phase I/II clinical trial, and its third product candidate, BHT-3034, for the treatment of myasthenia gravis, is in preclinical development.

This press release contains certain forward-looking statements that involve risks and uncertainties. Forward-looking statements include Bayhill’s plans to sell securities in an initial public offering. Such statements are only predictions and actual results may differ materially from those anticipated in these forward-looking statements.

Bayhill Therapeutics is the trademark of Bayhill Therapeutics, Inc.


More information about Bayhill Therapeutics is available at www.bayhilltx.com.